Advertisement

Search Results

Advertisement



Your search for ,HIS matches 4425 pages

Showing 2651 - 2700


Charles S. Fuchs, MD, MPH, to Lead Yale Cancer Center and Smilow Cancer Hospital

Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new Director and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven, effective January 1, 2017. Dr. Fuchs will be taking the reins of the Smilow Cancer...

Florida Atlantic University Appoints Phillip M. Boiselle, MD, as Dean of the Charles E. Schmidt College of Medicine

Florida Atlantic University has named Phillip M. Boiselle, MD, as the new Dean of the Charles E. Schmidt College of Medicine. Dr. ­Boiselle, who currently serves as Associate Dean for Academic and Clinical Affairs and Professor of Radiology at Harvard Medical School, and is a member of the...

Roger Stupp, MD, Appointed Associate Director for Strategic Initiatives at Robert H. Lurie Cancer Center

Swiss neuro-oncologist Roger Stupp, MD, has been appointed Associate Director for Strategic Initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. A leading authority on the treatment of primary and metastatic brain cancer, Dr. Stupp will join Northwestern...

breast cancer

Is Observation Without Surgery a Viable Strategy for Managing Ductal Carcinoma in Situ?

In a spirited debate, abounding with citations of clinical trials and other evidence, but not without humor and mutual respect, E. Shelley Hwang, MD, MPH, and Armando E. Giuliano, MD, reviewed the data and their clinical experience managing ductal carcinoma in situ and reached opposite...

Bruce Clurman, MD, PhD, Named Executive Vice President and Deputy Director of Fred Hutchinson Cancer Research Center

In his 25th year as a physician and researcher working at Fred Hutchinson Cancer Research Center, Bruce Clurman, MD, PhD, recently stepped into his newest role—Executive Vice President and Deputy Director of Fred Hutch. Fred Hutch President and Director Gary Gilliland, MD, PhD, recently announced...

pancreatic cancer

Scientists Are Boosting Immune Responses in Pancreatic Tumors

The successes observed with various immune oncologic treatment approaches have largely bypassed pancreatic cancer, but this may be about to change, based on emerging insights into how and why these tumors evade attacks by T cells. At the 2nd International Cancer Immunotherapy Conference, two...

skin cancer

Combination Strategies Harness the Power of the Oncolytic Virus Talimogene Laherparepvec

The injectable oncolytic immunotherapy talimogene laherparepvec (also known as T-VEC, Imlygic) may become a valuable component of combination immunotherapy approaches in melanoma, a strategy believed to help overcome resistance of tumors to single-agent immunotherapies. “[Talimogene laherparepvec] ...

issues in oncology

Putting Patients First: My Journey in Advocacy

When I lost my only sister to breast cancer in 1986, patients like her had devastatingly few choices. Over the intervening decades, sustained commitment to biomedical research at the National Institutes of Health (NIH) and major technologic advances have led to transformative changes in cancer...

Cedars-Sinai Appoints Robert A. Figlin, MD, to Lead New Initiative to Integrate Cancer Care Across Health System

Cedars-Sinai recently announced it has appointed Robert A. Figlin, MD, to integrate research and clinical strategies across the organization in an effort to standardize cancer care and ensure optimal treatment of patients. Dr. Figlin will serve as Deputy Director of the Integrated Oncology Service ...

palliative care

Quality Improvement Project Results in Timelier Hospice Referrals

A quality improvement project conducted within the OhioHealth system showed that oncologists can change their behavior and refer patients earlier to hospice care. After a relatively minor intervention, 18 medical oncologists in private practice doubled the mean length of stay in hospice care for...

leukemia

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Question 1: Which statement about donor selection for allogeneic hematopoietic cell transplant is correct? Correct Answer: C. If a donor is available, the genotypic identity between the patient and his brother should be established by typing the patient’s parents; if this is not possible, the...

leukemia

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Case Study A 33-year-old white male is diagnosed with acute myeloid leukemia (AML) with complex cytogenetics. A decision is made in favor of performing allogeneic hematopoietic cell transplantation in first complete remission. The patient has a 35-year-old brother who is healthy and motivated to...

genomics/genetics

Using Pharmacogenetics to Predict Cancer Prognosis, Response to Treatment, and Toxicity

Although clinical trials are helpful in determining the effectiveness of a specific drug across a patient population, they are not as reliable at pinpointing how well a particular patient will respond to the drug or dosing regimen or how the drug may impact the patient’s quality of life from...

skin cancer

Personalized Vaccines May Protect Patients With High-Risk Melanoma

The field of cancer vaccines may be reinvigorated by a new understanding, and the therapeutic leveraging, of neoantigens. Researchers from Dana-Farber Cancer Institute in Boston are exploring this novel approach as a means of protecting patients with high-risk melanoma from recurrence. Early...

When Breath Becomes Air: Dr. Lucy Kalanithi Reflects on Dr. Paul Kalanithi’s Life and Writing

Perhaps more than any other book in recent memory, When Breath Becomes Air has struck a chord among readers, both inside the medical community and among the public, desiring an honest and philosophical consideration of death. The autobiographical account of Paul Kalanithi, MD, a physician diagnosed ...

ASCO Presents First-Ever ASCO Congressional Leadership Award to Representative Michael Burgess, MD

ASCO presented Representative Michael Burgess, MD (TX-26) with the Society’s first-ever ASCO Congressional Leadership Award to recognize his steadfast work to advance policies that support cancer research and treatment. This new, annual award honors a Member of Congress who is a dedicated champion ...

Free PQRS Reporting Now Available Through QOPI®; No Additional Reporting Required

ASCO is pleased to announce that oncology practices can now complete all of their Physician Quality Reporting System (PQRS)1 requirements through the Quality Oncology Practice Initiative (QOPI®) platform. All users will be able to use the QOPI system to fulfill the Oncology Measures Group set of 7...

pancreatic cancer

Precision Promise Clinical Trial Focuses on Precision Medicine, Collaboration, and Data-Sharing in Pancreatic Cancer

The Pancreatic Cancer Action Network recently announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The organization also announced the 12 initial Precision Promise Clinical Trial Consortium sites selected to...

Expert Point of View: Olivier Michielin, MS, MD, PhD

The paper’s invited discussant was Olivier Michielin, MS, MD, PhD, Head of Personalized Analytical Oncology and the Melanoma Clinic at Lausanne University Hospital in Switzerland. He called the findings of the European Organisation for Research and Treatment (EORTC) 18071 trial a “new landmark in...

UPMC Honors Stanley M. Marks, MD, With Endowed Chair in Hematology/Oncology Leadership

The University of Pittsburgh Medical Center (UPMC) announced that Stanley M. Marks, MD, oncologist and advocate for cancer patients throughout the western Pennsylvania region, is being honored by the UPMC and his medical partners at Oncology Hematology Association (OHA) through the establishment...

head and neck cancer

With Changing Strategies for Laryngeal Cancer, Multidisciplinary Team Approach Is Key

The treatment of cancer of the larynx has changed dramatically in recent years. With organ preservation now possible in many cases, it is more important than ever for patients to receive guidance from every corner of the field. In a recent article in the Journal of Oncology Practice (JOP),1 a...

German Society Salutes ‘Big Four’ for Pioneering Work in Women’s Health Care

Diethelm Wallwiener, MD, President of the German Society for Gynaecology and Obstetrics, announced “The Big Four of the Millennium” at the 61st Congress of the Society, held recently in Stuttgart, Germany. The award recognizes individuals’ whose work in the 20th century created the standards of...

prostate cancer

Prognostic and Predictive Molecular Subtypes of Prostate Cancer Identified

Members of the oncology community have long complained that prostate cancer lags behind breast cancer regarding biomarkers for prognosis and treatment, but the good news is that this gap is narrowing. In the largest study of its kind to date, presented at the 58th Annual Meeting of the American...

Yanis Boumber, MD, PhD, Returns to Fox Chase, Department of Thoracic Oncology and Molecular Therapeutics Program

Yanis Boumber, MD, PhD, has joined the Department of Thoracic Medical Oncology and the Molecular Therapeutics Program at Fox Chase Cancer Center. Dr. Boumber first joined Fox Chase’s Department of Medical Oncology in 2013 and now returns to Fox Chase from the University of New Mexico Comprehensive ...

solid tumors
palliative care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near End of Life (French Language Version)

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit....

solid tumors
palliative care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract...

The University of Colorado Cancer Center Names Eric Clambey, PhD, Director of Flow Cytometry Shared Resource

The University of Colorado Cancer Center has named Eric Clambey, PhD, Director of the Flow Cytometry Shared Resource. Dr. Clambey, Assistant Professor in the Department of Anesthesiology, is excited to assume his new role in a vital resource for the cancer center. “My research focuses on the...

A Space to Heal

We pass them every day on our way to the hospital, the street dwellers of our town in India. Their home consists of a plastic sheet suspended between four poles on the pavement. One day, two women sat under the plastic sheet in happy conversation. It had rained heavily the previous night, and I...

Paul Jacobsen, PhD, Named Associate Director of National Cancer Institute Healthcare Delivery Research Program

Paul Jacobsen, PhD, has been named Associate Director of the National Cancer Institute (NCI) Division of Cancer Control and Population Science’s Healthcare Delivery Research Program.  In this position, he will be leading a team at the NCI whose mission is to serve as a catalyst for the field of...

Friendship

Mr. C is almost 90 now, but every summer the boxes of squash, pumpkins, tomatoes, and other vegetables from his truck farm still arrive like clockwork at our door. The cancer that required treatment 17 years ago has never recurred. He’s now struggling with a new problem, recovering from a broken...

Radiologic Associates of Fredericksburg Welcomes Samer Hijaz, MD

Radiologic Associates of Fredericksburg (RAF) has announced that Samer Hijaz, MD, a fellowship-trained interventional radiologist, has joined the practice. The interventional radiologists and vascular surgeons of the RAF serve patients at Virginia Interventional and Vascular Associates, the...

ASCO Recommends ‘Quick Wins’ for National Cancer Moonshot

Last month, ASCO recommended to Vice President Joe Biden several immediate and practical actions the Cancer Moonshot Initiative could take during the remainder of his term in the White House—steps that could make a lasting impact in the effort to discover new cancer treatments. ASCO’s...

ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term

Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...

Bishoy Faltas, MD, Joins Weill Cornell Medicine Hematology and Medical Oncology

On July 1, 2016, Bishoy Faltas, MD, joined the Genitourinary Oncology Program in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. As a laboratory-based physician-scientist, Dr. Faltas will focus on studying mechanisms of mutagenesis and drug resistance in bladder...

Eric Fearon, MD, PhD, Named Director of University of Michigan Comprehensive Cancer Center

Eric Fearon, MD, PhD, has been named Director of the University of Michigan Comprehensive Cancer Center. Dr. Fearon, the Emanuel N. Maisel Professor of Oncology at the University of Michigan, is a nationally recognized investigator in cancer genetics. His research has led to a greater...

head and neck cancer

Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer

When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...

John Karanicolas, PhD, Joins the Fox Chase Cancer Center Molecular Therapeutics Program

John Karanicolas, PhD, has joined the Fox Chase Cancer Center as Associate Professor in the Molecular Therapeutics Program. Dr. Karanicolas, a computational chemist, earned his doctorate from the Scripps Research Institute. He completed his postdoctoral fellowship at the University of Washington....

Friends of Cancer Research Honors Oncology Leaders at 20th Anniversary and Announces Partnership

Friends of Cancer Research (Friends) celebrated its 20th anniversary September 21 at a special event in Washington, DC. The event honored Janet Woodcock, MD; Eric Lander, PhD; and Sean Parker. Dr. Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug...

genomics/genetics

Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer

Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...

Oncology Researchers, Clinicians Selected as Endocrine Society 2017 Laureate Award Winners

The Endocrine Society selected 14 leaders in the endocrinology field as winners of the organization’s prestigious 2017 Laureate Awards. Established in 1944, the Laureate Awards recognize the highest achievements in the endocrinology field. Three oncology leaders in particular were recognized for...

Jacques Galipeau, MD, FRCP(C), Brings Personalized Stem Cell Treatment to UW Carbone

An international leader in harnessing a patient’s own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin (UW) Carbone Cancer Center on September 1. Jacques Galipeau, MD, FRCP(C), came from the Winship Cancer Center at Emory University, where he...

Internationally Renowned Statistician on Cancer Clinical Trials, Daniel J. Sargent, PhD, Dies

In the 20th century, the field of statistics developed and was gradually applied to clinical research. The use of statistics allows clinical researchers to form reasonable and accurate inferences from collected information and to make sound decisions in the presence of uncertainty. Moreover,...

palliative care

Palliative Care: Let’s Use the Tools We Already Have

Clinicians and researchers in the field of palliative and supportive care are enjoying the recognition the field is now receiving and expecting the future to be ripe with opportunity. But one thought leader in this specialty had a suggestion for attendees at the 2016 Palliative Care in Oncology...

issues in oncology
health-care policy
survivorship

Why Curing Cancer Will Take Decades

This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...

palliative care

Bridging the Gap in Oncology Care

The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...

ASCO Presents First-Ever Congressional Leadership Award to Rep. Michael Burgess, MD

ASCO presented Representative Michael Burgess, MD (TX-26) with its first-ever ASCO Congressional Leadership Award on September 21 to recognize his steadfast work to support policies related to cancer research and treatment. This new, annual award honors a member of Congress who is a consistent...

prostate cancer

Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?

The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...

lung cancer

Thomas J. Lynch, Jr, MD, on Personalized Care and Radiation Oncology in Lung Cancer

Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)

prostate cancer

Bradley R. Prestidge, MD, on Prostate Cancer: Initial Findings of NRG Oncology/RTOG 0232

Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer....

Brian Kavanagh, MD, MPH: Looking Ahead With ASTRO’s President-Elect

Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.

Advertisement

Advertisement




Advertisement